课题基金 / 基金详情

PLACEBO CONTROLLED STUDY OF LAMIVUDINE AND INTRON A IN CHRONIC HEPATITIS B

PLACEBO CONTROLLED STUDY OF LAMIVUDINE AND INTRON A IN CHRONIC HEPATITIS B
拉米夫定和内含子 A 在慢性乙型肝炎中的安慰剂对照研究
批准号：
6118403
负责人：
David Ian Kingston Martin
金额：
$2.51万
依托单位：
UNIVERSITY OF CALIFORNIA LOS ANGELES
依托单位国家：
美国
项目类别：
财政年份：
--
资助国家：
美国
项目状态：
未结题
起止时间：
至
来源：
https://reporter.nih.gov/project-details/6118403
关键词：
clinical research combination chemotherapy drug screening /evaluation hepatitis B hepatitis B virus group human subject human therapy evaluation immunopathology chemotherapy interferon alpha lamivudine microorganism disease chemotherapy placebos reverse transcriptase inhibitors

项目摘要

项目成果

David Ian Kingston Martin的其他基金

相似基金

相关文献

中文摘要
翻译
本研究的具体目的是：1)比较
英文摘要
The specific aims of this study are to: 1) compare the efficacy of lamivudine versus placebo versus lamivudine followed by the combination of lamivudine plus Intron A in patients with chronic hepatitis B infection who are interferon alpha non-responders; and 2) assess the safety of the three treatment regiments.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A high-throughput screen for candidate agents that may reverse gamma-globin silen
A high-throughput screen for candidate agents that may reverse gamma-globin silen
An Assay to Identify and Classify Epimutagens
An Assay to Identify and Classify Epimutagens
海外基金